Systematic review and meta‐analysis of surgical site infection following Mohs surgery without prophylactic antibiotics

Smith, Harvey R.; Borchard, Kate; Cherian, Paul; Vinciullo, Carl

doi:10.1111/ajd.13061

Cited by 3 publications

(2 citation statements)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The need for sterile surgical gowns and excessive full‐patient sterile draping should be questioned. Dermatologic surgery is a clean procedure and evidence points to the patient’s endogenous bacteria as the source of surgical site infection rather than factors pertaining to the surgeon and the operating theatre 40‐43 …”

Section: Recommendationsmentioning

confidence: 99%

“…Dermatologic surgery is a clean procedure and evidence points to the patient's endogenous bacteria as the source of surgical site infection rather than factors pertaining to the surgeon and the operating theatre. [40][41][42][43] Whilst it may be difficult to change hospital policy, simply switching to re-usable cotton surgical gowns and drapes would make a significant difference.…”

Section: Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Carbon footprint of dermatologic surgery

Tan¹,

Lim²

2020

Aust J Dermatology

View full text Add to dashboard Cite

Healthcare is a potent emitter of greenhouse gases amounting up to 7% of total estimated greenhouse gas emissions (CO 2 e) for Australia. Australia has one of the highest incidences of skin cancer in the world but there is a paucity of data on the ecological impact of skin cancer excision/dermatologic surgery. The authors reviewed the various impact inventories in order to perform a life cycle assessment of skin cancer excision. A total of 8641 tonnes of estimated CO 2 e are produced from dermatologic surgery annually in Australia (6751 tonnes from private clinical rooms and 1890 tonnes from hospitals) and the waste generated contributes significantly to terrestrial ecotoxicity and acidification of land and water. Various means can be carried out to reduce this impact, ranging from simple behavioural changes to larger, policy changes.

show abstract

Section: Recommendationsmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

Carbon footprint of dermatologic surgery

Tan¹,

Lim²

2020

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

Prophylactic Antibiotic Use in Reconstruction of Nasal Mohs Defects

Lee,

Longino,

Desisto

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of prophylactic antibiotics on outcomes and complications following surgical reconstructions of nasal Mohs defects in the outpatient setting.Study DesignRetrospective cohort study.SettingSingle tertiary care center, July 2021 to June 2023.MethodsAll adult patients who underwent reconstruction of nasal Mohs defects in an outpatient office setting were examined. Patient demographics, surgical details, prophylactic postprocedural antibiotic use, and postprocedural complications (infection, flap or graft necrosis, wound dehiscence) were collected. Outcomes and complications were compared between patients who received and did not receive prophylactic antibiotics using χ2, Kruskal‐Wallis, and multivariable logistic regression.ResultsA total of 211 patients met inclusion criteria. A majority of reconstructions utilized a local flap (70%), followed by a skin or composite graft (22%), then an interpolated flap (8%). Over half of patients (55%) were prescribed prophylactic antibiotics. Postprocedural complications were documented in 16 patients (7.6%), including infection (3.3%) and flap or graft loss or necrosis (1.4%). The rate of complications did not differ based on receipt of antibiotics. The only factors independently associated with the development of complications were history of chemoradiation and reconstruction with skin or composite grafts.ConclusionProphylactic antibiotics after nasal Mohs reconstructions performed in the office setting were not associated with any differences in the rate of postprocedural complications, including surgical site infections.

show abstract

Outcomes of Staged Excision With Circumferential en Face Margin Control for Lentigo Maligna of the Head and Neck

et al. 2020

View full text Add to dashboard Cite

Background Treatment practices vary for lentigo maligna (LM). Staged excision with circumferential margin control (SECMC) has the potential to achieve low recurrence rates. Objectives To evaluate the clinical outcomes of SECMC using permanent, paraffin-embedded sections and delayed reconstruction. Methods We conducted a retrospective, uncontrolled, observational cohort study involving patients who underwent staged excision for LM of the head and neck at Women’s College Hospital in Toronto, Canada, from September 2010 to March 2013. Recurrence and infection rates were ascertained from patient charts and postal surveys. Results One hundred and two patients (45 female, 57 male) were included with a median follow-up time of 1410.5 (IQR 260-1756) days. The median age was 69 (IQR 61-79) years. Approximately one-fifth (21%, 21/102) of patients required greater than 0.5 cm margins to achieve histological clearance. One patient (1/102) upstaged to invasive melanoma based on the initial stage of excision. The infection rate was 6% (6/102) and the 5-year cumulative recurrence rate was 1.4% (95% CI 0.2-9.6%). Conclusion SECMC using permanent sections and delayed reconstruction appears to be a safe and effective treatment method for LM on the head and neck. Randomized trials are needed to help define the optimal treatment.

show abstract

Systematic review and meta‐analysis of surgical site infection following Mohs surgery without prophylactic antibiotics

Cited by 3 publications

References 6 publications

Carbon footprint of dermatologic surgery

Carbon footprint of dermatologic surgery

Prophylactic Antibiotic Use in Reconstruction of Nasal Mohs Defects

Outcomes of Staged Excision With Circumferential en Face Margin Control for Lentigo Maligna of the Head and Neck

Contact Info

Product

Resources

About